Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymosin alpha 1 after radical resection for small hepatocellular carcinoma
ChiCTR-TRC-09000588Phase 4Completed
- Sponsor
- Liver Cancer Institute, Zhongshan Hospital, Fudan University
- Start
- Dec 2009
- Modality
- Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of thymosin alpha 1 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Liver Cancer Institute, Zhongshan Hospital, Fudan University. Primary endpoints: 1-year recurrence-free survival, 2-year recurrence-free survival and 2 more. Started Dec 2009; status: completed.
02
Drugs
thymosin alpha 1
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-09000588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000588.